Dicerna Pharmaceuticals (DRNA) Announces Closing Of Initial Public Offering And Exercise Of Option To Purchase Additional Shares
2/5/2014 5:09:53 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the closing of its initial public offering of 6,900,000 shares of common stock, including 900,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, at a public offering price of $15.00 per share, before underwriting discounts. The aggregate net proceeds to Dicerna, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $92.9 million. Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated acted as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated acted as co-lead manager for the offering.
Help employers find you! Check out all the jobs and post your resume.
comments powered by